Anti-MUC16 monoclonal antibody - Quest PharmaTech/AmrutBio

Drug Profile

Anti-MUC16 monoclonal antibody - Quest PharmaTech/AmrutBio

Alternative Names: Anti-MUC16 AR9.6; Anti-MUC16 mAb - Quest PharmaTech; AR 9.6; mAb-AR9.6

Latest Information Update: 30 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Nebraska Medical Center
  • Developer Quest PharmaTech
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 30 Sep 2016 Pharmacodynamics data from preclinical trials in Cancer released by QuestPharmatech (Quest PharmaTech website, September 2016)
  • 16 Sep 2016 Preclinical trials in Cancer in USA (IV) prior to September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top